Clinical Trial Update: Rituximab in IgG4-RD: A Phase 1-2 Trial [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating rituximab for IgG4-related disease has completed enrollment and posted results. The study examined retroperitoneal fibrosis, autoimmu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Pancreatitis
• Igg4-related Disease
• Pseudotumor
• Retroperitoneal Fibrosis
• Sialadenitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Retroperitoneal Fibrosis, Autoimmune Pancreatitis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-07-02